Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C. Broedl, and Hans J. Woerle, on behalf of the EMPA-REG BP Investigators Diabetes Care Volume 38: March, 2015 STUDY OBJECTIVE To investigate the efcacy, safety, and tolerability of empagliozin in patients with type 2 diabetes and hypertension Tikkanen I. et al. Diabetes Care 2015;38: STUDY DESIGN AND METHODS Patients with type 2 diabetes and hypertension were randomized to 10 or 25 mg empagliozin or placebo once daily for 12 weeks Tikkanen I. et al. Diabetes Care 2015;38: RESULTS At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h systolic blood pressure (SBP) was: mmHg with 10 mg empagliozin mmHg with 25 mg empagliozin At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h diastolic blood pressure (DBP) was: mmHg with 10 mg empagliozin mmHg with 25 mg empagliozin Tikkanen I. et al. Diabetes Care 2015;38: RESULTS Changes in ofce blood pressure were consistent with ambulatory blood pressure monitoring Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was 20.62% with 10 mg empagliozin and 20.65% with 25 mg empagliozin Empagliozin was well tolerated One patient on placebo and one patient on 10 mg empagliozin reported events consistent with volume depletion Tikkanen I. et al. Diabetes Care 2015;38: CONCLUSIONS Empagliozin was associated with signicant and clinically meaningful reductions in blood pressure and HbA1c versus placebo Empagliflozin was well tolerated in patients with type 2 diabetes and hypertension Tikkanen I. et al. Diabetes Care 2015;38: